Last reviewed · How we verify
Dilantin® Kapseals® 100 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Dilantin® Kapseals® 100 mg (Dilantin® Kapseals® 100 mg) — Mylan Pharmaceuticals Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dilantin® Kapseals® 100 mg TARGET | Dilantin® Kapseals® 100 mg | Mylan Pharmaceuticals Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dilantin® Kapseals® 100 mg CI watch — RSS
- Dilantin® Kapseals® 100 mg CI watch — Atom
- Dilantin® Kapseals® 100 mg CI watch — JSON
- Dilantin® Kapseals® 100 mg alone — RSS
Cite this brief
Drug Landscape (2026). Dilantin® Kapseals® 100 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/dilantin-kapseals-100-mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab